Review



vivo plustm rat igg2b isotype controls  (Bio X Cell)


Bioz Verified Symbol Bio X Cell is a verified supplier
Bioz Manufacturer Symbol Bio X Cell manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    Bio X Cell vivo plustm rat igg2b isotype controls
    Additive effect of the MRTX849/lapatinib combination on 4NQO-L sensitive tumors is modulated by the presence of CD8 + T-cells. A Growth curve (left) and tumor weight (right) of 4NQO-L tumors in WT mice treated with vehicle ( n = 5 mice, 10 tumors), MRTX849 ( n = 5 mice, 10 tumors), lapatinib ( n = 5 mice, 10 tumors), or the MRTX849/lapatinib combination ( n = 6 mice, 12 tumors). Error bars indicate SEM. Statistical significance was calculated using one-way ANOVA (**** p < 0.0001), ns denotes not significant. B IHC images showing the expression of Ki67 in tissue sections of 4NQO-L tumors treated with vehicle MRTX849, lapatinib, or the MRTX849/lapatinib combination (scale bars: 100 µm; inset 10 µm). n = 4 tumors and n = 27 analysis fields. Error bars indicate SD. Statistical significance was calculated using one-way ANOVA (** p < 0.01, **** p < 0.0001). C IHC images showing the infiltration of CD8 + T-cells in the tissue sections of 4NQO-L tumors treated with vehicle, MRTX849, lapatinib or the MRTX849/lapatinib combination (scale bar: 100 µm; inset: 10 µm). n = 4 tumors and n = 27 analysis fields. Error bars indicate SD. Statistical significance was calculated using one-way ANOVA (**** p < 0.0001). D Top: Tumor volume of the orthotopic 4NQO-L tumors in WT mice (left; n = 8 mice, 8 tumors) or NSG mice (right; n = 6 mice, 6 tumors) treated with vehicle or the MRTX849/lapatinib combination. Statistical significance was calculated using one-way ANOVA (**** p < 0.0001) Error bars indicate SEM. Bottom: Change in tumor volume from first to last day of treatment. E Top: Scheme of the experiment investigating the effect of CD8 + T-cell depletion on MRTX849/lapatinib efficacy. Bottom: Growth of 4NQO-L tumors in WT mice treated with <t>IgG</t> ( n = 6 mice, 11 tumors), αCD8 T cells depletion ( n = 6 mice, 12 tumors), IgG/MRTX849/lapatinib ( n = 5 mice, 10 tumors) or αCD8/MRTX849/lapatinib ( n = 6 mice, 12 tumors). Statistical significance was calculated using one-way ANOVA (**** p < 0.0001), ns denotes not significant
    Vivo Plustm Rat Igg2b Isotype Controls, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 96/100, based on 262 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/vivo+plustm+rat+igg2b+isotype+controls/pmc11577641-86-8-16?v=Bio+X+Cell
    Average 96 stars, based on 262 article reviews
    vivo plustm rat igg2b isotype controls - by Bioz Stars, 2026-08
    96/100 stars

    Images

    1) Product Images from "Dual inhibition of HERs and PD-1 counteract resistance in KRAS G12C -mutant head and neck cancer"

    Article Title: Dual inhibition of HERs and PD-1 counteract resistance in KRAS G12C -mutant head and neck cancer

    Journal: Journal of Experimental & Clinical Cancer Research : CR

    doi: 10.1186/s13046-024-03227-0

    Additive effect of the MRTX849/lapatinib combination on 4NQO-L sensitive tumors is modulated by the presence of CD8 + T-cells. A Growth curve (left) and tumor weight (right) of 4NQO-L tumors in WT mice treated with vehicle ( n = 5 mice, 10 tumors), MRTX849 ( n = 5 mice, 10 tumors), lapatinib ( n = 5 mice, 10 tumors), or the MRTX849/lapatinib combination ( n = 6 mice, 12 tumors). Error bars indicate SEM. Statistical significance was calculated using one-way ANOVA (**** p < 0.0001), ns denotes not significant. B IHC images showing the expression of Ki67 in tissue sections of 4NQO-L tumors treated with vehicle MRTX849, lapatinib, or the MRTX849/lapatinib combination (scale bars: 100 µm; inset 10 µm). n = 4 tumors and n = 27 analysis fields. Error bars indicate SD. Statistical significance was calculated using one-way ANOVA (** p < 0.01, **** p < 0.0001). C IHC images showing the infiltration of CD8 + T-cells in the tissue sections of 4NQO-L tumors treated with vehicle, MRTX849, lapatinib or the MRTX849/lapatinib combination (scale bar: 100 µm; inset: 10 µm). n = 4 tumors and n = 27 analysis fields. Error bars indicate SD. Statistical significance was calculated using one-way ANOVA (**** p < 0.0001). D Top: Tumor volume of the orthotopic 4NQO-L tumors in WT mice (left; n = 8 mice, 8 tumors) or NSG mice (right; n = 6 mice, 6 tumors) treated with vehicle or the MRTX849/lapatinib combination. Statistical significance was calculated using one-way ANOVA (**** p < 0.0001) Error bars indicate SEM. Bottom: Change in tumor volume from first to last day of treatment. E Top: Scheme of the experiment investigating the effect of CD8 + T-cell depletion on MRTX849/lapatinib efficacy. Bottom: Growth of 4NQO-L tumors in WT mice treated with IgG ( n = 6 mice, 11 tumors), αCD8 T cells depletion ( n = 6 mice, 12 tumors), IgG/MRTX849/lapatinib ( n = 5 mice, 10 tumors) or αCD8/MRTX849/lapatinib ( n = 6 mice, 12 tumors). Statistical significance was calculated using one-way ANOVA (**** p < 0.0001), ns denotes not significant
    Figure Legend Snippet: Additive effect of the MRTX849/lapatinib combination on 4NQO-L sensitive tumors is modulated by the presence of CD8 + T-cells. A Growth curve (left) and tumor weight (right) of 4NQO-L tumors in WT mice treated with vehicle ( n = 5 mice, 10 tumors), MRTX849 ( n = 5 mice, 10 tumors), lapatinib ( n = 5 mice, 10 tumors), or the MRTX849/lapatinib combination ( n = 6 mice, 12 tumors). Error bars indicate SEM. Statistical significance was calculated using one-way ANOVA (**** p < 0.0001), ns denotes not significant. B IHC images showing the expression of Ki67 in tissue sections of 4NQO-L tumors treated with vehicle MRTX849, lapatinib, or the MRTX849/lapatinib combination (scale bars: 100 µm; inset 10 µm). n = 4 tumors and n = 27 analysis fields. Error bars indicate SD. Statistical significance was calculated using one-way ANOVA (** p < 0.01, **** p < 0.0001). C IHC images showing the infiltration of CD8 + T-cells in the tissue sections of 4NQO-L tumors treated with vehicle, MRTX849, lapatinib or the MRTX849/lapatinib combination (scale bar: 100 µm; inset: 10 µm). n = 4 tumors and n = 27 analysis fields. Error bars indicate SD. Statistical significance was calculated using one-way ANOVA (**** p < 0.0001). D Top: Tumor volume of the orthotopic 4NQO-L tumors in WT mice (left; n = 8 mice, 8 tumors) or NSG mice (right; n = 6 mice, 6 tumors) treated with vehicle or the MRTX849/lapatinib combination. Statistical significance was calculated using one-way ANOVA (**** p < 0.0001) Error bars indicate SEM. Bottom: Change in tumor volume from first to last day of treatment. E Top: Scheme of the experiment investigating the effect of CD8 + T-cell depletion on MRTX849/lapatinib efficacy. Bottom: Growth of 4NQO-L tumors in WT mice treated with IgG ( n = 6 mice, 11 tumors), αCD8 T cells depletion ( n = 6 mice, 12 tumors), IgG/MRTX849/lapatinib ( n = 5 mice, 10 tumors) or αCD8/MRTX849/lapatinib ( n = 6 mice, 12 tumors). Statistical significance was calculated using one-way ANOVA (**** p < 0.0001), ns denotes not significant

    Techniques Used: Expressing

    MRTX849/lapatinib/αPD-1 treatment is ineffective in MRTX849-resistant tumors. A Growth curve of 4NQO-L KRAS G12C i acquired resistant tumors in WT mice treated with vehicle, MRTX849, lapatinib or MRTX849/lapatinib combination ( n = 6 mice, 12 tumors). B IHC images showing the infiltration of CD8 + T cells in the tissue sections of 4NQO-L KRAS G12C i acquired-resistance tumors treated with vehicle MRTX849, lapatinib, or MRTX849/lapatinib (scale bars: 100 µm; inset 10 µm). n = 4 tumors and n = 40 analysis fields. Error bars indicate SD. Statistical significance was calculated using one-way ANOVA (** p < 0.01, *** p < 0.001, **** p < 0.0001). C IHC images showing expression of PD-L1 in the tissue sections of 4NQO-L KRAS G12C i acquired resistant tumors treated with vehicle, MRTX849, lapatinib or MRTX849/lapatinib (scale bars: 100 µm; inset 10 µm). n = 4 tumors and n = 38 analysis fields. Error bars indicate SD. Statistical significance was calculated using one-way ANOVA (* p < 0.05, *** p < 0.001, **** p < 0.0001), ns denotes not significant. D IHC images showing the expression of αSMA in the tissue sections of 4NQO-L KRAS G12C i acquired resistant tumors treated with vehicle, MRTX849, lapatinib or MRTX849/lapatinib (scale bars: 100 µm; inset 10 µm). n = 4 tumors and n = 40 analysis fields. Error bars indicate SD. Statistical significance was calculated using one-way ANOVA (**** p < 0.0001), ns denotes not significant. E IHC images showing the infiltration of CD8 + T-cells in the tissue sections of 4NQO-L KRAS G12C i-acquired-resistance tumors (scale bars: 100 µm; inset 10 µm). n = 4 tumors and n = 41 analysis fields. Error bars indicate SD. Statistical significance was calculated using one-way ANOVA (**** p < 0.0001). F Growth curves of 4NQO-L KRAS G12C i-acquired-resistance tumors treated with IgG, IgG/MRTX849/lapatinib, MRTX849/αPD-1, or the combination of MRTX849/ lapatinib and αPD-1 ( n = 6 mice, 12 tumors). Statistical significance was calculated using one-way ANOVA, ns denotes not significant
    Figure Legend Snippet: MRTX849/lapatinib/αPD-1 treatment is ineffective in MRTX849-resistant tumors. A Growth curve of 4NQO-L KRAS G12C i acquired resistant tumors in WT mice treated with vehicle, MRTX849, lapatinib or MRTX849/lapatinib combination ( n = 6 mice, 12 tumors). B IHC images showing the infiltration of CD8 + T cells in the tissue sections of 4NQO-L KRAS G12C i acquired-resistance tumors treated with vehicle MRTX849, lapatinib, or MRTX849/lapatinib (scale bars: 100 µm; inset 10 µm). n = 4 tumors and n = 40 analysis fields. Error bars indicate SD. Statistical significance was calculated using one-way ANOVA (** p < 0.01, *** p < 0.001, **** p < 0.0001). C IHC images showing expression of PD-L1 in the tissue sections of 4NQO-L KRAS G12C i acquired resistant tumors treated with vehicle, MRTX849, lapatinib or MRTX849/lapatinib (scale bars: 100 µm; inset 10 µm). n = 4 tumors and n = 38 analysis fields. Error bars indicate SD. Statistical significance was calculated using one-way ANOVA (* p < 0.05, *** p < 0.001, **** p < 0.0001), ns denotes not significant. D IHC images showing the expression of αSMA in the tissue sections of 4NQO-L KRAS G12C i acquired resistant tumors treated with vehicle, MRTX849, lapatinib or MRTX849/lapatinib (scale bars: 100 µm; inset 10 µm). n = 4 tumors and n = 40 analysis fields. Error bars indicate SD. Statistical significance was calculated using one-way ANOVA (**** p < 0.0001), ns denotes not significant. E IHC images showing the infiltration of CD8 + T-cells in the tissue sections of 4NQO-L KRAS G12C i-acquired-resistance tumors (scale bars: 100 µm; inset 10 µm). n = 4 tumors and n = 41 analysis fields. Error bars indicate SD. Statistical significance was calculated using one-way ANOVA (**** p < 0.0001). F Growth curves of 4NQO-L KRAS G12C i-acquired-resistance tumors treated with IgG, IgG/MRTX849/lapatinib, MRTX849/αPD-1, or the combination of MRTX849/ lapatinib and αPD-1 ( n = 6 mice, 12 tumors). Statistical significance was calculated using one-way ANOVA, ns denotes not significant

    Techniques Used: Expressing



    Similar Products

    vivo plustm rat igg2b isotype controls  (Bio X Cell)
    96
    Bio X Cell vivo plustm rat igg2b isotype controls
    Additive effect of the MRTX849/lapatinib combination on 4NQO-L sensitive tumors is modulated by the presence of CD8 + T-cells. A Growth curve (left) and tumor weight (right) of 4NQO-L tumors in WT mice treated with vehicle ( n = 5 mice, 10 tumors), MRTX849 ( n = 5 mice, 10 tumors), lapatinib ( n = 5 mice, 10 tumors), or the MRTX849/lapatinib combination ( n = 6 mice, 12 tumors). Error bars indicate SEM. Statistical significance was calculated using one-way ANOVA (**** p < 0.0001), ns denotes not significant. B IHC images showing the expression of Ki67 in tissue sections of 4NQO-L tumors treated with vehicle MRTX849, lapatinib, or the MRTX849/lapatinib combination (scale bars: 100 µm; inset 10 µm). n = 4 tumors and n = 27 analysis fields. Error bars indicate SD. Statistical significance was calculated using one-way ANOVA (** p < 0.01, **** p < 0.0001). C IHC images showing the infiltration of CD8 + T-cells in the tissue sections of 4NQO-L tumors treated with vehicle, MRTX849, lapatinib or the MRTX849/lapatinib combination (scale bar: 100 µm; inset: 10 µm). n = 4 tumors and n = 27 analysis fields. Error bars indicate SD. Statistical significance was calculated using one-way ANOVA (**** p < 0.0001). D Top: Tumor volume of the orthotopic 4NQO-L tumors in WT mice (left; n = 8 mice, 8 tumors) or NSG mice (right; n = 6 mice, 6 tumors) treated with vehicle or the MRTX849/lapatinib combination. Statistical significance was calculated using one-way ANOVA (**** p < 0.0001) Error bars indicate SEM. Bottom: Change in tumor volume from first to last day of treatment. E Top: Scheme of the experiment investigating the effect of CD8 + T-cell depletion on MRTX849/lapatinib efficacy. Bottom: Growth of 4NQO-L tumors in WT mice treated with <t>IgG</t> ( n = 6 mice, 11 tumors), αCD8 T cells depletion ( n = 6 mice, 12 tumors), IgG/MRTX849/lapatinib ( n = 5 mice, 10 tumors) or αCD8/MRTX849/lapatinib ( n = 6 mice, 12 tumors). Statistical significance was calculated using one-way ANOVA (**** p < 0.0001), ns denotes not significant
    Vivo Plustm Rat Igg2b Isotype Controls, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/vivo+plustm+rat+igg2b+isotype+controls/pmc11577641-86-8-16?v=Bio+X+Cell
    Average 96 stars, based on 1 article reviews
    vivo plustm rat igg2b isotype controls - by Bioz Stars, 2026-08
    96/100 stars
    		  Buy from Supplier

    Image Search Results


    Additive effect of the MRTX849/lapatinib combination on 4NQO-L sensitive tumors is modulated by the presence of CD8 + T-cells. A Growth curve (left) and tumor weight (right) of 4NQO-L tumors in WT mice treated with vehicle ( n = 5 mice, 10 tumors), MRTX849 ( n = 5 mice, 10 tumors), lapatinib ( n = 5 mice, 10 tumors), or the MRTX849/lapatinib combination ( n = 6 mice, 12 tumors). Error bars indicate SEM. Statistical significance was calculated using one-way ANOVA (**** p < 0.0001), ns denotes not significant. B IHC images showing the expression of Ki67 in tissue sections of 4NQO-L tumors treated with vehicle MRTX849, lapatinib, or the MRTX849/lapatinib combination (scale bars: 100 µm; inset 10 µm). n = 4 tumors and n = 27 analysis fields. Error bars indicate SD. Statistical significance was calculated using one-way ANOVA (** p < 0.01, **** p < 0.0001). C IHC images showing the infiltration of CD8 + T-cells in the tissue sections of 4NQO-L tumors treated with vehicle, MRTX849, lapatinib or the MRTX849/lapatinib combination (scale bar: 100 µm; inset: 10 µm). n = 4 tumors and n = 27 analysis fields. Error bars indicate SD. Statistical significance was calculated using one-way ANOVA (**** p < 0.0001). D Top: Tumor volume of the orthotopic 4NQO-L tumors in WT mice (left; n = 8 mice, 8 tumors) or NSG mice (right; n = 6 mice, 6 tumors) treated with vehicle or the MRTX849/lapatinib combination. Statistical significance was calculated using one-way ANOVA (**** p < 0.0001) Error bars indicate SEM. Bottom: Change in tumor volume from first to last day of treatment. E Top: Scheme of the experiment investigating the effect of CD8 + T-cell depletion on MRTX849/lapatinib efficacy. Bottom: Growth of 4NQO-L tumors in WT mice treated with IgG ( n = 6 mice, 11 tumors), αCD8 T cells depletion ( n = 6 mice, 12 tumors), IgG/MRTX849/lapatinib ( n = 5 mice, 10 tumors) or αCD8/MRTX849/lapatinib ( n = 6 mice, 12 tumors). Statistical significance was calculated using one-way ANOVA (**** p < 0.0001), ns denotes not significant

    Journal: Journal of Experimental & Clinical Cancer Research : CR

    Article Title: Dual inhibition of HERs and PD-1 counteract resistance in KRAS G12C -mutant head and neck cancer

    doi: 10.1186/s13046-024-03227-0

    Figure Lengend Snippet: Additive effect of the MRTX849/lapatinib combination on 4NQO-L sensitive tumors is modulated by the presence of CD8 + T-cells. A Growth curve (left) and tumor weight (right) of 4NQO-L tumors in WT mice treated with vehicle ( n = 5 mice, 10 tumors), MRTX849 ( n = 5 mice, 10 tumors), lapatinib ( n = 5 mice, 10 tumors), or the MRTX849/lapatinib combination ( n = 6 mice, 12 tumors). Error bars indicate SEM. Statistical significance was calculated using one-way ANOVA (**** p < 0.0001), ns denotes not significant. B IHC images showing the expression of Ki67 in tissue sections of 4NQO-L tumors treated with vehicle MRTX849, lapatinib, or the MRTX849/lapatinib combination (scale bars: 100 µm; inset 10 µm). n = 4 tumors and n = 27 analysis fields. Error bars indicate SD. Statistical significance was calculated using one-way ANOVA (** p < 0.01, **** p < 0.0001). C IHC images showing the infiltration of CD8 + T-cells in the tissue sections of 4NQO-L tumors treated with vehicle, MRTX849, lapatinib or the MRTX849/lapatinib combination (scale bar: 100 µm; inset: 10 µm). n = 4 tumors and n = 27 analysis fields. Error bars indicate SD. Statistical significance was calculated using one-way ANOVA (**** p < 0.0001). D Top: Tumor volume of the orthotopic 4NQO-L tumors in WT mice (left; n = 8 mice, 8 tumors) or NSG mice (right; n = 6 mice, 6 tumors) treated with vehicle or the MRTX849/lapatinib combination. Statistical significance was calculated using one-way ANOVA (**** p < 0.0001) Error bars indicate SEM. Bottom: Change in tumor volume from first to last day of treatment. E Top: Scheme of the experiment investigating the effect of CD8 + T-cell depletion on MRTX849/lapatinib efficacy. Bottom: Growth of 4NQO-L tumors in WT mice treated with IgG ( n = 6 mice, 11 tumors), αCD8 T cells depletion ( n = 6 mice, 12 tumors), IgG/MRTX849/lapatinib ( n = 5 mice, 10 tumors) or αCD8/MRTX849/lapatinib ( n = 6 mice, 12 tumors). Statistical significance was calculated using one-way ANOVA (**** p < 0.0001), ns denotes not significant

    Article Snippet: In vivo PlusTM anti-mouse CD8α or IgG (In vivo PlusTM rat IgG2b) isotype controls, both from Bio X Cell, were used for CD8 depletion experiments.

    Techniques: Expressing

    MRTX849/lapatinib/αPD-1 treatment is ineffective in MRTX849-resistant tumors. A Growth curve of 4NQO-L KRAS G12C i acquired resistant tumors in WT mice treated with vehicle, MRTX849, lapatinib or MRTX849/lapatinib combination ( n = 6 mice, 12 tumors). B IHC images showing the infiltration of CD8 + T cells in the tissue sections of 4NQO-L KRAS G12C i acquired-resistance tumors treated with vehicle MRTX849, lapatinib, or MRTX849/lapatinib (scale bars: 100 µm; inset 10 µm). n = 4 tumors and n = 40 analysis fields. Error bars indicate SD. Statistical significance was calculated using one-way ANOVA (** p < 0.01, *** p < 0.001, **** p < 0.0001). C IHC images showing expression of PD-L1 in the tissue sections of 4NQO-L KRAS G12C i acquired resistant tumors treated with vehicle, MRTX849, lapatinib or MRTX849/lapatinib (scale bars: 100 µm; inset 10 µm). n = 4 tumors and n = 38 analysis fields. Error bars indicate SD. Statistical significance was calculated using one-way ANOVA (* p < 0.05, *** p < 0.001, **** p < 0.0001), ns denotes not significant. D IHC images showing the expression of αSMA in the tissue sections of 4NQO-L KRAS G12C i acquired resistant tumors treated with vehicle, MRTX849, lapatinib or MRTX849/lapatinib (scale bars: 100 µm; inset 10 µm). n = 4 tumors and n = 40 analysis fields. Error bars indicate SD. Statistical significance was calculated using one-way ANOVA (**** p < 0.0001), ns denotes not significant. E IHC images showing the infiltration of CD8 + T-cells in the tissue sections of 4NQO-L KRAS G12C i-acquired-resistance tumors (scale bars: 100 µm; inset 10 µm). n = 4 tumors and n = 41 analysis fields. Error bars indicate SD. Statistical significance was calculated using one-way ANOVA (**** p < 0.0001). F Growth curves of 4NQO-L KRAS G12C i-acquired-resistance tumors treated with IgG, IgG/MRTX849/lapatinib, MRTX849/αPD-1, or the combination of MRTX849/ lapatinib and αPD-1 ( n = 6 mice, 12 tumors). Statistical significance was calculated using one-way ANOVA, ns denotes not significant

    Journal: Journal of Experimental & Clinical Cancer Research : CR

    Article Title: Dual inhibition of HERs and PD-1 counteract resistance in KRAS G12C -mutant head and neck cancer

    doi: 10.1186/s13046-024-03227-0

    Figure Lengend Snippet: MRTX849/lapatinib/αPD-1 treatment is ineffective in MRTX849-resistant tumors. A Growth curve of 4NQO-L KRAS G12C i acquired resistant tumors in WT mice treated with vehicle, MRTX849, lapatinib or MRTX849/lapatinib combination ( n = 6 mice, 12 tumors). B IHC images showing the infiltration of CD8 + T cells in the tissue sections of 4NQO-L KRAS G12C i acquired-resistance tumors treated with vehicle MRTX849, lapatinib, or MRTX849/lapatinib (scale bars: 100 µm; inset 10 µm). n = 4 tumors and n = 40 analysis fields. Error bars indicate SD. Statistical significance was calculated using one-way ANOVA (** p < 0.01, *** p < 0.001, **** p < 0.0001). C IHC images showing expression of PD-L1 in the tissue sections of 4NQO-L KRAS G12C i acquired resistant tumors treated with vehicle, MRTX849, lapatinib or MRTX849/lapatinib (scale bars: 100 µm; inset 10 µm). n = 4 tumors and n = 38 analysis fields. Error bars indicate SD. Statistical significance was calculated using one-way ANOVA (* p < 0.05, *** p < 0.001, **** p < 0.0001), ns denotes not significant. D IHC images showing the expression of αSMA in the tissue sections of 4NQO-L KRAS G12C i acquired resistant tumors treated with vehicle, MRTX849, lapatinib or MRTX849/lapatinib (scale bars: 100 µm; inset 10 µm). n = 4 tumors and n = 40 analysis fields. Error bars indicate SD. Statistical significance was calculated using one-way ANOVA (**** p < 0.0001), ns denotes not significant. E IHC images showing the infiltration of CD8 + T-cells in the tissue sections of 4NQO-L KRAS G12C i-acquired-resistance tumors (scale bars: 100 µm; inset 10 µm). n = 4 tumors and n = 41 analysis fields. Error bars indicate SD. Statistical significance was calculated using one-way ANOVA (**** p < 0.0001). F Growth curves of 4NQO-L KRAS G12C i-acquired-resistance tumors treated with IgG, IgG/MRTX849/lapatinib, MRTX849/αPD-1, or the combination of MRTX849/ lapatinib and αPD-1 ( n = 6 mice, 12 tumors). Statistical significance was calculated using one-way ANOVA, ns denotes not significant

    Article Snippet: In vivo PlusTM anti-mouse CD8α or IgG (In vivo PlusTM rat IgG2b) isotype controls, both from Bio X Cell, were used for CD8 depletion experiments.

    Techniques: Expressing